{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:04:07Z","timestamp":1774073047818,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40123-025-01139-6","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:08:29Z","timestamp":1747062509000},"page":"1349-1356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancing Ocular Safety Profile Assessment: A Novel Grading Scale for Ocular Adverse Reactions Associated with Bemarituzumab"],"prefix":"10.1007","volume":"14","author":[{"given":"Asim V.","family":"Farooq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Hundal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosilin","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Zahlten-K\u00fcmeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumera","family":"Raoof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhezhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Telma","family":"Murias Dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun Jacqueline","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Colby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"issue":"35","key":"1139_CR1","doi-asserted-by":"publisher","first-page":"58709","DOI":"10.18632\/oncotarget.17634","volume":"8","author":"C Fu","year":"2017","unstructured":"Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2017;8(35):58709\u201327.","journal-title":"Oncotarget"},{"issue":"26","key":"1139_CR2","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.2011.41.5851","volume":"30","author":"DJ Renouf","year":"2012","unstructured":"Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. J Clin Oncol. 2012;30(26):3277\u201386.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1139_CR3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1755-3768.2012.02518.x","volume":"91","author":"WL Ho","year":"2013","unstructured":"Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol. 2013;91(7):604\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"25","key":"1139_CR4","doi-asserted-by":"publisher","first-page":"15292","DOI":"10.1074\/jbc.271.25.15292","volume":"271","author":"DM Ornitz","year":"1996","unstructured":"Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, et\u00a0al. Receptor specificity of the fibroblast growth factor family*. J Biol Chem. 1996;271(25):15292\u20137.","journal-title":"J Biol Chem"},{"issue":"7","key":"1139_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/002215549704500710","volume":"45","author":"SE Hughes","year":"1997","unstructured":"Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem. 1997;45(7):1005\u201319.","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"1139_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117089","volume":"10","author":"J Zhang","year":"2015","unstructured":"Zhang J, Upadhya D, Lu L, Reneker LW. Fibroblast growth factor receptor 2 (FGFR2) is required for corneal epithelial cell proliferation and differentiation during embryonic development. PLoS ONE. 2015;10(1):e0117089.","journal-title":"PLoS ONE"},{"issue":"13","key":"1139_CR7","first-page":"3418","volume":"45","author":"MA Kirby","year":"2004","unstructured":"Kirby MA, Johnston MD. Expression of fibroblast growth factor receptors (FGFR 1\u20135) in fetal and adult human retina. Investig Ophthalmol Vis Sci. 2004;45(13):3418.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"11","key":"1139_CR8","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","volume":"28","author":"AB Lassman","year":"2022","unstructured":"Lassman AB, Sep\u00falveda-S\u00e1nchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, et\u00a0al. Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study. Clin Cancer Res. 2022;28(11):2270\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1139_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","volume":"23","author":"AO Siefker-Radtke","year":"2022","unstructured":"Siefker-Radtke AO, Necchi A, Park SH, Garc\u00eda-Donas J, Huddart RA, Burgess EF, et\u00a0al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23(2):248\u201358.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1139_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Iannotti N, Gutierrez M, Smith D, F\u00e9liz L, Lihou C, et\u00a0al. FIGHT-101, a first-in-human study of potent and selective FGFR 1\u20133 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies. Ann Oncol. 2022;33(5):522\u201333.","journal-title":"Ann Oncol"},{"issue":"1","key":"1139_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.survophthal.2023.09.007","volume":"69","author":"J Hsu","year":"2024","unstructured":"Hsu J, Francis JH, Ahmad S. Ocular toxicities of fibroblast growth factor receptor inhibitors: a review. Surv Ophthalmol. 2024;69(1):34\u201341.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"1139_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Wainberg ZA, Enzinger PC, Kang Y-K, Qin S, Yamaguchi K, Kim I-H, et\u00a0al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11):1430\u201340.","journal-title":"Lancet Oncol"},{"key":"1139_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00710","volume":"9","author":"SY Rha","year":"2025","unstructured":"Rha SY, Zhang Y, Elme A, Pazo Cid R, Alacacioglu A, Ziogas DC, et\u00a0al. Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial. JCO Precis Oncol. 2025;9:e2400710.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"1139_CR14","doi-asserted-by":"publisher","first-page":"1981202","DOI":"10.1080\/19420862.2021.1981202","volume":"13","author":"H Xiang","year":"2021","unstructured":"Xiang H, Chan AG, Ahene A, Bellovin DI, Deng R, Hsu AW, et\u00a0al. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021;13(1):1981202.","journal-title":"MAbs"},{"issue":"3","key":"1139_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","volume":"27","author":"ZA Wainberg","year":"2024","unstructured":"Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, et\u00a0al. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024;27(3):558\u201370.","journal-title":"Gastric Cancer"},{"issue":"21","key":"1139_CR16","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1200\/JCO.19.01834","volume":"38","author":"DVT Catenacci","year":"2020","unstructured":"Catenacci DVT, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, et\u00a0al. Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. J Clin Oncol. 2020;38(21):2418\u201326.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1139_CR17","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/ijms25020849","volume":"25","author":"KS Shan","year":"2024","unstructured":"Shan KS, Dalal S, Thaw Dar NN, McLish O, Salzberg M, Pico BA. Molecular targeting of the fibroblast growth factor receptor pathway across various cancers. Int J Mol Sci. 2024;25(2):849.","journal-title":"Int J Mol Sci"},{"key":"1139_CR18","unstructured":"National Cancer Institute (NCI) on the Cancer Therapy Evaluation Program (CTEP) website. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0: Updated November 27, 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf."},{"issue":"8","key":"1139_CR19","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1167\/iovs.02-1100","volume":"44","author":"DA Rosser","year":"2003","unstructured":"Rosser DA, Cousens SN, Murdoch IE, Fitzke FW, Laidlaw DA. How sensitive to clinical change are ETDRS logMAR visual acuity measurements? Invest Ophthalmol Vis Sci. 2003;44(8):3278\u201381.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1139_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41433-022-02180-6","volume":"38","author":"P de Jong","year":"2024","unstructured":"de Jong P. A history of visual acuity testing and optotypes. Eye (Lond). 2024;38(1):13\u201324.","journal-title":"Eye (Lond)"},{"issue":"4","key":"1139_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/opo.12310","volume":"36","author":"DB Elliott","year":"2016","unstructured":"Elliott DB. The good (logMAR), the bad (Snellen) and the ugly (BCVA, number of letters read) of visual acuity measurement. Ophthalmic Physiol Opt. 2016;36(4):355\u20138.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"4","key":"1139_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/bjo.85.4.432","volume":"85","author":"DA Rosser","year":"2001","unstructured":"Rosser DA, Laidlaw DA, Murdoch IE. The development of a \u201creduced logMAR\u201d visual acuity chart for use in routine clinical practice. Br J Ophthalmol. 2001;85(4):432\u20136.","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01139-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01139-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01139-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T07:49:47Z","timestamp":1749887387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01139-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01139-6","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Asim V. Farooq: Ambrx, Amgen, Eisai, GlaxoSmithKline, Mythic Therapeutics, Sanofi, Seagen\/Pfizer, Skye Bioscience (consultant), AstraZeneca (member of data monitoring committee); Savreet Kaur: Amgen (employee and stockholder); Pradeep Hundal: Amgen (employee); Maureen Burke: Amgen (employee and stockholder), Arcus Biosciences, Astex Pharmaceuticals, Taiho Oncology (past employment); Rosilin Sulaiman: Amgen (employee); Anita Zahlten-Kuemeli: Amgen (employee and stockholder); Sumera Raoof: Amgen (employee and stockholder); Zhezhen Li: Amgen (employee and stockholder); Telma Murias Dos Santos: Amgen (employee and stockholder); Xiaojun Huang: Amgen (employee and stockholder); Kathryn Colby: Amgen (consultant).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}